Integra Lifesciences Holdings (IART) Cash & Current Investments (2009 - 2026)

Integra Lifesciences Holdings has disclosed Cash & Current Investments across 18 years of filings, most recently posting $274.1 million for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 8.08% year-over-year to $274.1 million; the TTM figure through Jun 2026 stood at $274.1 million (up 8.08% YoY), while the FY2025 annual figure was $263.7 million, down 3.59% from the prior year.
• Cash & Current Investments came in at $274.1 million for Q2 2026 at Integra Lifesciences Holdings, up from $265.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $663.1 million in Q1 2024 to a low of $253.6 million in Q2 2025.
• Average Cash & Current Investments over 5 years is $340.6 million, with a median of $287.3 million recorded in 2024.
• Year-over-year, Cash & Current Investments jumped 115.74% in 2024 and plunged 58.78% in 2025.
• Over 5 years, Cash & Current Investments stood at $456.7 million in 2022, then tumbled by 32.31% to $309.1 million in 2023, then fell by 11.49% to $273.6 million in 2024, then retreated by 3.59% to $263.7 million in 2025, then advanced by 3.93% to $274.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $274.1 million in Q2 2026, $265.5 million in Q1 2026, and $263.7 million in Q4 2025.